CARA Overzicht aandelen
Cara Therapeutics, Inc., een biofarmaceutisch bedrijf in een ontwikkelingsstadium, richt zich op de ontwikkeling en commercialisering van therapeutica voor de behandeling van chronische pruritus in de Verenigde Staten.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Cara Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.30 |
| 52 Week Hoogtepunt | US$1.40 |
| 52 Week Laag | US$0.24 |
| Bèta | 0.70 |
| 11 maand verandering | 7.76% |
| 3 maanden verandering | -17.89% |
| 1 Jaar Verandering | -77.67% |
| 33 jaar verandering | -98.28% |
| 5 jaar verandering | -98.60% |
| Verandering sinds IPO | -97.70% |
Recent nieuws en updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18Recent updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19Rendement voor aandeelhouders
| CARA | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 10.0% | -3.7% | -1.6% |
| 1Y | -77.7% | 17.2% | 30.8% |
Rendement versus industrie: CARA underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.
Rendement versus markt: CARA underperformed the US Market which returned 30.8% over the past year.
Prijsvolatiliteit
| CARA volatility | |
|---|---|
| CARA Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: CARA has not had significant price volatility in the past 3 months compared to the US market.
Volatiliteit in de loop van de tijd: CARA's weekly volatility has decreased from 17% to 9% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2004 | 55 | Chris Posner | www.caratherapeutics.com |
Cara Therapeutics, Inc., een biofarmaceutisch bedrijf in ontwikkelingsfase, richt zich op de ontwikkeling en commercialisering van therapeutica voor de behandeling van chronische pruritus in de Verenigde Staten. Het belangrijkste product van het bedrijf is KORSUVA (difelikefalin) injectie voor de behandeling van matige tot ernstige pruritus geassocieerd met chronische nierziekte (CKD) bij volwassenen die hemodialyse ondergaan. Het ontwikkelt ook oraal difelikefaline, dat zich in Fase II/III van de klinische studie bevindt voor de behandeling van chronische pruritus met notalgia paresthetica.
Cara Therapeutics, Inc. Samenvatting
| CARA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$16.29m |
| Inkomsten(TTM) | -US$111.08m |
| Inkomsten(TTM) | US$11.00m |
1.5x
P/S-verhouding-0.1x
Koers/WinstverhoudingIs CARA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CARA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$11.00m |
| Kosten van inkomsten | US$88.85m |
| Brutowinst | -US$77.85m |
| Overige uitgaven | US$33.23m |
| Inkomsten | -US$111.08m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.03 |
| Brutomarge | -707.98% |
| Nettowinstmarge | -1,010.19% |
| Schuld/Eigen Vermogen Verhouding | 342.1% |
Hoe presteerde CARA op de lange termijn?
Bekijk historische prestaties en vergelijking